Document is current
Any future updates will be listed below
-
Authors
Ray, Jason C. https://orcid.org/0000-0003-4833-5507
Darby, David
Butzkueven, Helmut
Matharu, Manjit S.
Hutton, Elspeth J.
-
Funding
Funding for this research was provided by:
Monash University
- License Information
-
More Information
Article History
Received: 27 February 2024
Accepted: 4 April 2024
First Online: 12 April 2024
Declarations
:
: This study received institutional review board approval (Alfred Health HREC 153/21). Patients provided informed consent to participate in this study.
: Dr. Ray has received funding for educational activity from Abbvie, Novartis and Viatris. He has served on medical advisory boards for Pfizer, Viatris, and Lilly. Professor Butzkueven’s institution (Monash University) received compensation for consulting, talks, and advisory/steering board activities from Alfred Health, Biogen, Merck, Novartis, Roche and UCB; research support from Biogen, Merck, MS Research Australia, National Health and Medical Research (Australia), Medical Research Future Funds (Australia) Novartis, the Oxford Health Policy Forum, and Roche. He has received personal compensation for steering group activities from Oxford Health Policy Forum. Prof. Matharu serves on the advisory board for Allergan, Novartis, Eli Lilly, Autonomic Technologies Inc and TEVA and has received payment for the development of educational presentations from Allergan, electroCore, Eli Lilly, Novartis and TEVA. Dr. Hutton has served on advisory boards for Sanofi-Genzyme, Novartis, Teva, Eli Lilly, Allergan, Lundbeck, been involved in clinical trials sponsored by Novartis, Teva, Xalud, Cerecin, and has received payment for educational presentations from Allergan, Teva, Eli Lilly and Novartis.
